Urinary Fibroblast Growth Factor-23 and Soluble Alpha-Klotho in Cats with Chronic Kidney Disease
Authors:
- 21 March 2026
- journal article
- Published by Elsevier in The Veterinary Journal
- Vol. 317, 106652
Abstract
No abstract availableKeywords
Funding Information
- National Taiwan University Hospital
This publication has 61 references indexed in Scilit:
- Renal Clearance of Fibroblast Growth Factor-23 (FGF23) and its Fragments in HumansJournal of Bone and Mineral Research, 2022
- Considerations in Controlling for Urine Concentration for Biomarkers of Kidney Disease Progression After Acute Kidney InjuryKidney International Reports, 2022
- Urinary Biomarkers and Kidney Outcomes: Impact of Indexing Versus Adjusting for Urinary CreatinineKidney Medicine, 2021
- C-terminal and intact FGF23 in critical illness and their associations with acute kidney injury and in-hospital mortalityCytokine, 2018
- Klotho Ameliorates Kidney Injury and Fibrosis and Normalizes Blood Pressure by Targeting the Renin-Angiotensin SystemThe American Journal of Pathology, 2015
- Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patientsPediatric Nephrology, 2015
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney diseaseBone, 2009
- Klotho is a substrate for α‐, β‐ and γ‐secretaseFEBS Letters, 2009
- Klotho suppresses TNF-α-induced expression of adhesion molecules in the endothelium and attenuates NF-κB activationEndocrine, 2009